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Abstract
Background: Telomere shortening is associated with increasing age, male gender and lifestyle factors such as
obesity and smoking. Inflammation has also been implicated in cellular senescence and may promote telomere
shortening in chronic conditions such as obesity and diabetes. However, little is known about the relationship
between markers of obesity and inflammation, and leukocyte telomere length (LTL).
Methods: LTL was measured using quantitative polymerase chain reaction in peripheral leukocytes from 295
individuals diagnosed with Barrett’s esophagus (BE) between 1995 and 2009. Data on lifestyle variables including
obesity and smoking were collected at in-person interviews. Biomarkers of obesity (leptin, adiponectin), diabetes
(glucose, insulin), inflammation (C-reactive protein, Interleukin-6, surface tumor necrosis factor receptor (sTNFR) I &
II) and oxidative stress (F2-isoprostanes) were measured in stored blood samples. We examined associations
between these covariates and LTL in a cross-sectional analysis using linear and logistic regression models, adjusting
for possible confounders.
Results: LTL was significantly associated with age (r = −0.30, p < 0.001), gender (r = 0.14 for females, p = 0.01) and
inversely associated with cigarette pack-years (r = −0.11, p = 0.04). Odds of having short LTL were significantly higher
for participants in the highest tertile for sTNF-RI (Odds ratio adjusted for age, gender, smoking, and obesity = 2.19;
95 % CI 1.00–4.85, p-trend = 0.02). LTL was not significantly associated with any other lifestyle factors, including
smoking or obesity, or other inflammation-, obesity-/diabetes-related biomarkers measured.
Conclusions: Increasing age, male gender, smoking history, and sTNF-RI levels were associated with short LTL
among persons with BE but no correlations were observed between LTL and other inflammatory markers or
measures of obesity. Larger longitudinal studies are necessary in order to further establish the potential
relationships between obesity, inflammation markers and LTL.
Background
Telomeres are the protective structures that cap the
ends of eukaryotic chromosomes, consisting of a large
number of tandem DNA repeats bound to a variety
of proteins [1]. They protect chromosomes from end-
to-end fusion, degradation and atypical recombination
[2]. Telomeres shorten with each cell division, and
when telomeres reach a critical threshold, cellular
senescence is triggered via DNA damage checkpoint
mechanisms [1, 2]. Hence, telomere length has been
considered as a biomarker for ageing.
Telomere shortening has consistently been associated
with older age [3, 4], male gender [3, 4] and Caucasian
race [5]. Shorter telomeres have also been shown to be
associated with lifestyle factors such as obesity [6], and
smoking [6], but these associations have not been
consistent across studies [7]. Telomere shortening has
been established as a risk factor for chronic conditions
such as cardiovascular disease [4] and diabetes [8].
Additionally, telomere shortening has been observed
early in precursor lesions for various cancers [9], and
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epidemiological studies have suggested shortened telo-
meres as potential biomarkers of cancer incidence and
mortality [10, 11], including cancers of the esophagus
[12] and stomach [13].
Inflammation and oxidative stress have been associated
with ageing in general [14], and shortening of telomeres in
particular [15, 16]. Oxidative stress and resulting reactive
oxygen species may cause single-stranded breaks in
telomeric DNA either directly or indirectly through
improper DNA repair [17]. Chronic conditions such
as obesity and diabetes may also affect telomere
length by promoting inflammation; studies have impli-
cated adipokines in the development of insulin resist-
ance, accelerated cell senescence and ageing [18].
Although it is hypothesized that inflammation may
contribute to telomere shortening by accelerating cellular
turnover [19] particularly among obese individuals, the
relationship between systemic markers of obesity, dia-
betes, and inflammation, and leukocyte telomere length
(LTL) remains to be better elucidated.
Barrett’s esophagus (BE), the only identified precur-
sor of esophageal adenocarcinoma, is a metaplastic
condition of the esophagus where the normal squa-
mous epithelium is replaced by a specialized type of
columnar intestinal epithelium, usually as a result of
chronic gastroesophageal reflux [20]. It is estimated
to occur in 2–4 % of adults in the US. Central adiposity
has been shown to be a strong and common risk factor
for BE; together with gastroesophageal reflux, these risk
factors cause chronic inflammation both in the esophageal
tissue as well systemically [21].
In this cross-sectional analysis, we evaluated corre-
lations between LTL, measured by quantitative poly-
merase chain reaction, and demographic and lifestyle
factors including obesity and smoking, and systemic
biomarkers of obesity, diabetes, and inflammation, in
a subset of the Seattle Barrett’s esophagus study
(SBES) cohort, who were diagnosed between 1995
and 2009. As most persons with BE are obese and
have significant underlying systemic inflammation,
this cohort provided a good opportunity to under-




The SBES is a prospective cohort study aimed at identify-
ing factors that predict neoplastic progression in persons
with BE, a precursor to esophageal adenocarcinoma.
Participants underwent a personal interview at enrollment
along with dietary and anthropometric assessments,
endoscopy with biopsies and collection of blood samples,
details of which have been previously described [22, 23].
We used baseline data on 295 individuals that had LTL
measurements available at baseline, to test cross-sectional
associations between LTL and demographic and lifestyle
factors. Of the 295 with available LTL measurements, 202
had biomarker measurements available at baseline while
32 had biomarkers measured within a year from their
baseline visit. We used biomarker data from these 234
individuals to test the associations between LTL and
markers of inflammation, diabetes and obesity. Partici-
pants with C-reactive protein (CRP) levels greater than
10 mg/L (n = 12) were omitted from analysis involving
CRP due to an a priori hypothesis that they may be a
result of acute inflammation. Institutional Review Boards
at the University of Washington and Fred Hutchinson
Cancer Research Center approved the study. Written,
informed consent was obtained from all the participants
prior to study enrollment.
Covariates
Anthropometric measurements, including body mass
index (BMI), waist circumference (WC) and waist-hip
ratio (WHR) were measured as described previously
[22]. Cigarette use was described as ever use (at least
one cigarette/day for six months or longer) and cigarette
pack-years of smoking (number of cigarette packs
smoked per day times number of years smoked). Alcohol
consumption was computed after combining responses
for beer, wine and liquor intake. A history of NSAID and
statin use was also collected at baseline, as reported
previously [23, 24].
Assays
Participants provided fasting venous blood samples
which were processed within 2 hours after collection
and stored at −80 °C until analysis. Intra- and inter-assay
coefficients of variation (CVs) were calculated by includ-
ing blind duplicate samples with each laboratory batch,
as described previously [25, 26]. Briefly, inflammation
markers measured and their intra- and inter-batch CVs
are respectively: CRP (immunonephelometry; Dade
Behring; inter-batch CV 2.88 %), interleukin-6 (IL-6;
Quantikine HS human IL-6 Elisa kit; R&D Systems;
CVs 4.13 % and 4.35 %), soluble tumor necrosis
factor receptor- I & II (sTNFR-I & II; MILLIPLEX
MAP Human Soluble Cytokine Receptor Panel; Millipore;
sTNFR-I CVs 5.87 % and 8.93 %, sTNFR-II CVs 2.39 %
and 6.09 %), F2-isoprostanes (gas chromatography/ mass
spectrometry; 6890 N Agilent gas chromatograph & 5973
quadruple mass spectrometer; precision ±3 %). We also
measured several obesity- and diabetes-related markers
on stored blood samples, details of which have been
described previously [27]. These included leptin (Linco
Research Human leptin radioimmunoassay; Millipore,
Billerica, MA), adiponectin (multimeric enzyme-linked
immunosorbent assay; ALPCO Diagnostic, Salem, NH),
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glucose (Clinical Chemistry Autoanalyzer, using the
glucose/hexokinase procedure), and insulin (Tosoh
autoanalyzer; Tosoh Bioscience, Inc, San Francisco, CA);
the intra- and inter-assay coefficients for these assays
ranged from 1.4 to 11.9 %. Homeostatic model assessment
(HOMA) score was computed from the insulin and
glucose measurements [27]. Laboratory personnel were
blinded to other exposures and outcomes.
LTL analysis
Genomic DNA was extracted from buffy coat prepara-
tions stored at −80 °C and telomere length was mea-
sured using quantitative polymerase chain reaction [28].
A relative unitless measure of telomere length, T/S ratio,
was computed by dividing the amount of telomeric
DNA (T) with the amount of single-copy control gene
(S). All measurements were performed in triplicate and
the median was used for all calculations. In addition,
two internal control DNA samples were run within each
plate to evaluate inter-plate variation. For T/S ratios, the
intra- and inter-assay CVs were 6 % and 7 %, respect-
ively. The mean T/S ratio of the cohort was standardized
to have a mean of 0 and a standard deviation of 1.0 to
enable comparisons within the cohort.
Statistical analysis
Medians and standard deviations for continuous vari-
ables and proportions for categorical variables were
computed by telomere tertiles. Age- and gender-adjusted
correlations between various participant characteristics,
including biomarker levels, and LTL were investigated
with Pearson product–moment correlations as well as
linear regression models. LTL was the dependent
variable in the linear regression models.LTL and bio-
marker measures were normally distributed hence were
not log transformed but rather used in their original
form for analyses. We further assessed whether selected
participant characteristics and higher levels of obesity
and inflammation biomarkers were associated with
increased odds for short telomere length (shortest
telomere tertile; T/S ratio < 0.735). Biomarkers were evalu-
ated as continuous measures, and categorized as tertiles.
For every variable of interest, three different models were
run: unadjusted, age- and gender-adjusted, and further
adjusted for smoking and obesity, both major correlates of
inflammation [29, 30]. Odds ratios (ORs) and 95 % confi-
dence intervals (CIs) were calculated using unconditional
logistic regression models. Tests for trend were based on
the likelihood-ratio test associated with addition of the
variable of interest in its continuous form. Sensitivity
analyses were conducted after dropping those that had
biomarker measurements within a year of baseline visit.
Results with p-values less than 0.05 were considered to
be statistically significant. All statistical analyses were
carried out using STATA statistical software (version
12.0; Stata Corp).
Results
Participant characteristics within telomere tertiles are
shown in Table 1 along with results of the correlation
and linear regression analysis. LTL was the dependent
variable in these analyses. On average, participants were
60.9 years, overweight (average BMI = 29.2 kg/m2),
predominantly male (80 %), and 66 % were either
current or past smokers (66 %).
Gender-adjusted LTL was inversely correlated with
age (r = −0.30, p < 0.0001) with an attrition rate of
0.003 ± 0.001 per year in the T/S ratio. LTL was signifi-
cantly longer in females compared to males (r = 0.14 for
females, p =0.01), in an age-adjusted model. There was
little evidence of an association between telomere length
and any of the obesity-related variables such as BMI
(p =0.35), WHR (p = 0.38) or WC (p = 0.14) in the
linear regression models. Cumulative smoking exposure
measured as cigarette pack-years smoked negatively corre-
lated with LTL (r = −0.11, p = 0.04), and the association
remained statistically significant after adjustment for
age and gender in the linear regression model [β
(95 % CI) = −0.0006 (−0.0011,-0.0000); p = 0.04]. Use
of medications such as NSAIDs and statins, and alcohol
consumption were not associated with LTL. Further
adjustment for confounding effects of obesity and
smoking did not change any results presented in Table 1
(data not shown).
Table 2 displays the correlations and linear associa-
tions between biomarkers and LTL. No significant asso-
ciation with LTL was observed in linear regression
models with obesity/diabetes-related biomarkers includ-
ing leptin and adiponectin, glucose, insulin, or HOMA
score. While there was a trend towards an inverse cor-
relation between LTL and biomarkers of inflammation,
none of these associations were statistically significant.
Adjustment by age, gender, smoking and obesity had no
effect on the results (data not shown).
To identify any non-linear associations between short
LTL and biomarkers and/or participant characteristics,
we examined whether higher levels of biomarkers were
associated with increased odds of short LTL in logistic
regression models (Table 3). Each one year increase in
age increased the odds of short telomeres by 4 % (OR
adjusted for gender, smoking and obesity =1.04, 95 %
CI 1.02–1.07). Females were 63 % less likely to have
short telomeres than males (OR adjusted for age,
smoking and obesity =0.37, 95 % CI 0.18–0.78). None
of the obesity-related variables (BMI, WHR or WC)
or smoking variables (ever use and pack-years) were
associated with short LTL in logistic regression models.
Analyses on obesity- and diabetes-related biomarkers also
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Table 1 Study participant characteristics and their linear associations with leukocyte telomere lengtha










Age & gender adjusted




295 0.68 (0.05) 0.78 (0.03) 0.90 (0.08) - - -
Age (per year) † 295 65.5 (10.9) 62.0 (12.0) 57.0 (10.8) −0.30₤ −0.003 (−0.004,-0.002)₤ <0.001
Gender ‡ Male 236 84 (87.5) 78 (78.8) 74 (74.0) - REF -
Female 59 12 (12.5) 21 (21.2) 26 (26.0) - 0.04 (0.01,0.07)€ 0.01
BMI (per kg/m2) † 290 28.1 (3.6) 29.2 (4.5) 29.1 (4.3) 0.05 0.002 (−0.002,0.005) 0.35
Waist-hip ratio
(per unit) †
294 0.95 (0.06) 0.96 (0.07) 0.95 (0.07) 0.05 0.10 (−0.13, 0.34) 0.38
Waist circumference
(per inch) †
294 39.2 (4.0) 39.6 (4.9) 39.6 (4.4) 0.09 0.002 (−0.001, 0.005) 0.14
Cigarette use ‡ Never 100 33 (34.4) 29 (29.3) 38 (38.0) - REF -
Ever 195 63 (65.6) 70 (70.7) 62 (62.0) - −0.007 (−0.03, 0.02) 0.64
Cigarette pack-years
(per pack-year) †
195 34.0 (25.6) 23.6 (24.8) 18.5 (19.1) −0.11 −0.0006 (−0.0011,−0.0000) 0.04
Alcoholic drinks/day
(per drink) †
240 1.7 (4.9) 1.4 (7.9) 1.0 (2.5) −0.07 −0.002 (−0.004, 0.001) 0.20
NSAID use ‡ Non-current 190 58 (60.4) 64 (64.7) 68 (68.0) - REF -
Current 105 38 (39.6) 35 (35.3) 32 (32.0) - −0.001 (−0.029, 0.027) 0.93
Statin use ‡ Non-current 265 83 (86.5) 92 (92.9) 90 (90.0) - REF
Current 30 13 (13.5) 7 (7.1) 10 (10.0) - −0.023 (−0.066, 0.020) 0.29
Leukocyte telomere length tertile: Short < 0.735, Middle 0.735-0.846, Long ≥ 0.847
† =Median (Standard deviation), ‡ = Frequency (%), ₤ = Adjusted only for gender, ¶ = Adjusted for age & gender
BMI body mass index, NSAID non-steroidal anti-inflammatory drugs, CI confidence interval
aThe correlation and regression values are based on leukocyte telomere length as a continuous variable
Table 2 Biomarker concentrations and their linear associations with leukocyte telomere lengthc




n Short (n = 76) Middle (n = 80) Long (n = 78) Age & gender adjusted beta (95 % CI) P-value
Leptin (ng/ml) 287 7.8 (10.3) 9.5 (12.3) 10.1 (10.3) −0.01 −0.0001 (−0.002, 0.002) 0.90
Total adiponectin (mcg/ml) 226 5.2 (2.8) 5.4 (2.4) 4.4 (2.5) −0.01 −0.001 (−0.007, 0.006) 0.88
HMW adiponectin (mcg/ml) 226 1.9 (1.7) 2.0 (1.6) 1.8 (1.6) 0.01 0.001 (−0.010, 0.011) 0.90
Glucose (mg/dL) 226 91.0 (14.6) 91.5 (28.4) 93.0 (30.3) 0.04 0.0002 (−0.0004, 0.0008) 0.52
Insulin (uU/ml) 226 7.2 (5.2) 6.4 (7.7) 6.9 (5.4) −0.001 −0.0001 (−0.0024, 0.0024) 0.99
HOMA score 226 1.6 (1.3) 1.5 (3.3) 1.6 (1.7) 0.01 0.0003 (−0.006, 0.007) 0.93
C-reactive protein (mg/L) 222 2.1 (2.3) 1.8 (2.5) 2.3 (2.1) −0.04 −0.002 (−0.009, 0.005) 0.57
Interleukin-6 (pg/ml) 234 2.1 (2.7) 2.0 (2.9) 1.7 (1.6) −0.10 −0.005 (−0.011, 0.001) 0.11
sTNF-RI (ng/ml) 234 1.5 (0.5) 1.3 (0.4) 1.3 (0.5) −0.06 −0.016 (−0.050, 0.020) 0.36
sTNF-RII (ng/ml) 234 5.6 (1.6) 5.3 (1.5) 5.0 (1.1) −0.003 −0.0003 (−0.012, 0.011) 0.96
F2-isoprostanes (pg/ml) 224 54.0 (34.2) 57.5 (26.5) 54.0 (38.3) −0.04 −0.0002 (−0.0006, 0.0003) 0.53
Leukocyte telomere length tertile: Short < 0.735, Middle 0.735-0.846, Long ≥ 0.847
sTNF-RI & RII soluble tumor necrosis factor receptor I & II, HMW high molecular weight, HOMA score homeostatic model assessment score
aAdjusted for age & gender
bMedian (standard deviation)
cThe correlation and regression values are based on leukocyte telomere length as a continuous variable
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Table 3 Odds ratios (OR) for short LTLa by subject characteristics and markers of inflammation
Characteristic N Unadjusted OR
(95 % CI)
Age & gender adjusted
OR (95 % CI)
Age, gender, smoking & obesity€
adjusted OR (95 % CI)
Age (per year) 295 1.05 (1.03,1.07) 1.05 (1.03,1.08) ₤ 1.04 (1.02,1.07) ₤
Gender (Females vs. males) 295 0.46 (0.23,0.92) 0.43 (0.21,0.87) € 0.37 (0.18,0.78) €
BMI (per kg/m2) 290 0.91 (0.85,0.97) 0.93 (0.87,1.00) 0.96 (0.86,1.07)
Waist circumference (per inch) 294 0.96(0.91,1.02) 0.94(0.88,1.00) 0.94 (0.88,1.00)
Waist-hip ratio (per unit) 294 1.11(0.77,1.60) 0.72(0.45,1.16) 0.92 (0.49,1.74)
Cigarette use (Ever vs. never) 295 1.01 (1.00,1.03) 1.01 (0.99,1.03) 0.99 (0.96,1.03)
Pack-years continuous (per pack-year) 295 1.01 (1.00,1.02) 1.01 (1.00,1.02) 1.01 (1.00,1.02)
Pack-years Tertiles -
Non-smokers REF REF REF
T1 (0.05-) 0.58 (0.28,1.20) 0.64 (0.30,1.35) 0.64 (0.30,1.37)
T2 (14-) 0.91 (0.47,1.76) 0.79 (0.40,1.57) 0.84 (0.42,1.70)
T3 (36-) 1.58 (0.83,3.01) 1.30 (0.66,2.56) 1.40 (0.70,2.77)
p-trendb 0.04** 0.27 0.20
Leptin (ng/ml) 226 0.98 (0.95,1.01) 1.00 (0.97,1.04) 1.05 (1.01,1.12)
Total Adiponectin
(mcg/ml)
226 1.08 (0.97,1.20) 1.00 (0.88,1.15) 0.98 (0.85,1.12)
HMW Adiponectin (mcg/ml) 226 1.10 (0.92,1.30) 0.98 (0.79,1.21) 0.92 (0.74,1.15)
Glucose (mg/dL) 226 0.99 (0.98,1.01) 0.99 (0.97,1.01) 0.99 (0.97,1.01)
Insulin (uU/ml) 226 1.00 (0.95,1.04) 1.00 (0.95,1.05) 1.02 (0.97,1.07)
HOMA score 226 0.95 (0.82,1.09) 0.95 (0.81,1.12) 1.01 (0.86,1.18)
CRP continuous (mg/L) 222 0.98 (0.87,1.11) 0.95 (0.82,1.09) 0.98 (0.84,1.13)
CRP Tertiles
T1 (0.1-) REF REF REF
T2 (1.1-) 1.36 (0.67,2.74) 1.40 (0.66,2.96) 1.69 (0.78,3.68)
T3 (2.9-) 0.91 (0.45,1.85) 0.81 (0.37,1.78) 1.04 (0.45,2.40)
p-trendb 0.74 0.44 0.74
IL-6 continuous (pg/ml) 234 1.06 (0.95,1.17) 1.02 (0.90,1.15) 1.04 (0.92,1.18)
IL-6 Tertiles
T1 (0.4-) REF REF REF
T2 (1.5-) 1.45 (0.74,2.86) 1.21 (0.58,2.50) 1.25 (0.59,2.62)
T3 (2.6-) 1.25 (0.63-2.47) 1.07 (0.50,2.31) 1.22 (0.55,2.71)
p-trendb 0.32 0.77 0.51
sTNF-RI continuous (ng/ml) 234 3.30 (1.75,6.23) 2.02 (1.02,3.99) 2.30 (1.11,4.78)
sTNF-RI Tertiles
T1 (0.3-) REF REF REF
T2 (1.2-) 1.14 (0.56,2.33) 0.90 (0.42,1.91) 1.00 (0.46,2.15)
T3 (1.5-) 3.25 (1.64,6.43) 1.81 (0.85,3.84) 2.19 (1.00,4.85)
p-trendb <0.001** 0.04** 0.02 **
sTNF-RII continuous (ng/ml) 234 1.30 (1.07,1.58) 1.08 (0.86,1.35) 1.06 (0.84,1.33)
sTNF-RII Tertiles
T1 (2.1-) REF REF REF
T2 (4.9-) 0.90 (0.44,1.82) 0.64 (0.30,1.37) 0.68 (0.32,1.47)
T3 (6.0-) 2.52 (1.29,4.90) 1.42 (0.66,3.04) 1.45 (0.67,3.15)
p-trendb 0.01** 0.50 0.62
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did not show any significant results. When viewed on a
continuous scale, increasing sTNF-RI levels were asso-
ciated with increased odds of short LTL (OR adjusted
for age, gender, smoking and obesity =2.30, 95 % CI
1.11–4.78. A significant trend was observed with
sTNF-RI such that those in the highest tertile were at
more than twice increased odds of having short telo-
meres as compared to those in the lowest tertile (OR
adjusted for age, gender, smoking and obesity =2.19,
95 % CI 1.00–4.85, p-trend = 0.02).Although the
unadjusted odds for short LTL were significant for
sTNF-RII, this association disappeared after adjust-
ment for confounders, including age, gender, smoking,
and obesity. There were no significant associations
observed between short LTL and higher levels of
CRP, IL-6 or F2-isoprostanes.
To better understand the interrelationship between
obesity and inflammation markers in relation to LTL,
we also evaluated the effect of adjustment for obesity
on the relationship between inflammation markers
and telomere length as well as the effect of adjust-
ment for inflammation markers on the obesity-
telomere length relationship for all the models. We
observed that further adjustment for obesity increased
the odds for short telomeres (e.g. further adjustment
for obesity, as measured by waist circumference,
increases the OR for shortest sTNF-RI telomere
tertile from 2.00 (95 % CI 0.99–4.03) to 2.30 (95 %
CI 1.11–4.78) after adjusting for obesity.
We also conducted separate sensitivity analyses after
excluding measurements from 32 individuals that had
their biomarkers measured within one year of ba-
seline so as to completely exclude the possibility of
reverse causality. We found that the linear association
for cigarette pack-years of smoking got slightly weaker
(r = −0.06) and did not hold statistical significance after
age and gender adjustment. The positive result for
sTNF-RI also did not change significantly when we
excluded the 32 individuals whose measurements were
taken within one year of baseline (Adjusted OR = 2.32,
95 % CI 0.98–5.46). The trend for sTNF-RI tertiles also
remained significant even after dropping the 32 measure-
ments (p-trend = 0.04).
Discussion
In this cross-sectional study we found evidence linking a
serum-based marker of inflammation, elevated sTNF-RI,
with shortened LTL. Individuals with sTNF-RI levels in
the highest tertile were at 2.2 times increased odds of
having short LTL compared to those individuals with
sTNF-RI levels in the lowest tertile. We also found
suggestive evidence of a trend of shorter LTL with
increasing sTNF-RII levels, although this was not signifi-
cant after adjustment for confounders. As we expected,
we also observed associations between LTL and age,
gender and smoking.
Our findings are in line with previous research
regarding associations of LTL with demographic and
lifestyle characteristics. A recent review by Sanders et. al.
summarized the utility of telomere length as a biomarker
for ageing in epidemiological studies and established
increasing age and male gender to be most consistently
associated with shorter LTL across studies [7]. The
evidence regarding smoking has been mixed [7]. Some
studies have reported a positive association with LTL [31],
while others have reported negative association [3, 4].
To date, there are limited data on the association
between inflammatory biomarkers and LTL. Reports that
have observed an association between increasing levels
of inflammation markers and short LTL are few in
number [4, 15, 16, 32]. One hypothesis that may explain
a cross-sectional association between LTL and inflam-
mation suggests that inflammation may accelerate
telomere attrition by enhancing leukocyte turnover
and replicative senescence [33]. Shorter telomeres may
also cause programmed cell death and lead to accumula-
tion of excessive senescent cells which in turn may be
responsible for the elevated levels of inflammation
markers [19, 34]. A factor supporting this hypothesis is
that the main sources for TNF-α secretion (and thereby
Table 3 Odds ratios (OR) for short LTLa by subject characteristics and markers of inflammation (Continued)
F2-isoprostanes continuous (pg/ml) 224 1.00 (0.99,1.01) 1.00 (1.00,1.01) 1.01 (1.00,1.02)
F2-isoprostane Tertiles
T1 (14-) REF REF REF
T2 (48-) 0.62 (0.31,1.25) 0.67 (0.32,1.41) 0.72 (0.34,1.52)
T3 (67-) 0.93 (0.48,1.83) 1.28 (0.60,2.71) 1.55 (0.71,3.39)
p-trendb 0.88 0.31 0.18
LTL leukocyte telomere length, BMI body mass index, CRP c-reactive protein, IL-6 interleukin-6, sTNF-RI & RII Soluble tumor necrosis factor receptor I & II, CI
confidence interval
£ - Adjusted for cigarette pack-years smoked at baseline, € - Adjusted for waist circumference at baseline, ₤ = Adjusted only for gender, € = Adjusted only for age
** p-value significant at 0.05 level
aShort LTL defined as lowest tertile (T/S ratio < 0.735)
bTest for trend based on the likelihood-ratio test associated with addition of the variable under consideration in its continuous form
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shedding of the soluble TNF receptors), fibroblasts and
mononuclear cells, are both involved in clearing of the
senescent cells from the body [35]. In the present analysis,
we only found associations with LTL for sTNF receptors,
particularly sTNF-RI. Moreover, this association was
apparent only in logistic regression models (no association
was found in linear models). We are not sure of the
robustness of this finding with sTNF-RI as the cut-points
for both short telomeres and sTNF receptor tertiles were
arbitrary, and this significant finding with sTNF-RI may
be entirely data driven. Additionally, we also evaluated
interrelationships between obesity and inflammation with
respect to LTL. We observed that the age, gender, and
smoking adjusted OR’s became stronger after further
adjustment for obesity in inflammation-LTL association
models. These results suggest that visceral adiposity and
inflammation markers may independently influence
telomere length. However, as these results are based
on a cross-sectional analysis, any inferences on temporal-
ity should be drawn with caution, and further evaluation
in a longitudinal setting is necessary to better understand
this relationship.
Very few studies have evaluated the association of LTL
with obesity/diabetes-related biomarkers such as leptin,
adiponectin [36, 37], or insulin, glucose or HOMA
scores [8, 38]. The rationale behind these studies is similar
to that behind studies of the inflammation-LTL relation-
ship i.e. the presence of these chronic conditions may give
rise to increased turnover of cells, and ultimately shorter
telomeres. Results from previous studies show positive
associations with some obesity and diabetes markers and
negative associations with others, that do not seem to be
patterned on populations studied [7]. A recent meta-
analysis reported an inverse association with leptin and no
association with adiponectin [37]. However, this study
only adjusted for confounding effects of BMI and was not
able to adjust for central adiposity measures such as waist-
hip circumference or waist circumference. In addition to
adjusting for a likely more predictive measure of adiposity
(waist circumference), we were also able to adjust for smok-
ing, an important confounder in the association between
obesity and LTL. Our results did not show a significant
association of LTL with any of the obesity/diabetes-related
biomarkers evaluated. We were not able to replicate the
inverse association with leptin demonstrated in the meta-
analysis by Broer et. al [37]. This may be due to a smaller
sample size of our study but may also be due to a more
complete adjustment for confounding in our study relative
to the meta-analysis.
Our study was limited by the cross-sectional design
as it does not allow for temporal interpretations. The
sample size is also limited. This may partially contrib-
ute to why we were unable to observe any association
between telomere length and obesity/diabetes. There
is also a possibility that the association observed with
sTNF-RI might be a chance finding as we conducted
multiple statistical tests in the limited sample size
available. The study participants were a high-risk cohort
of BE patients, many being obese (38 %). This might have
resulted in higher levels of both obesity and inflammation
markers among the study participants as compared to
the general population [30]. This can be viewed upon
as both a strength and a limitation. On the one hand,
we did not encounter the problem of a large propor-
tion of biomarkers being below detection limit, while
on the other hand, the higher inflammation levels in
this cohort make the results from this study less
generalizable to other populations. Although we con-
trolled for confounding in multivariable analysis, there
is a possibility of residual confounding. In addition,
we cannot exclude the possibility of measurement
error in the estimation of biomarkers, driving the risk
estimates towards the null (assuming non-differential
measurement error). Strengths of our study include a
well characterized study population with detailed informa-
tion on important confounders and reliable laboratory
measurements judged by blinded QC samples embedded
in the study samples.
Conclusions
In summary, the present study shows that the inflamma-
tion marker sTNF-RI, is significantly associated with short
LTL among persons with BE. In addition, we confirmed
previous findings of shortened telomeres with increasing
age, male gender and increasing pack-years of smoking.
No association was observed between biomarkers of
obesity/diabetes and short LTL. In order to further
establish the potential relationship between obesity,
inflammation and telomere length, larger longitudinal
studies are needed.
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